Davis Polk advised the representatives of the several underwriters in connection with the $240 million initial public offering of 12,650,000 shares of common stock of Olema Oncology at $19.00 per share (which includes the exercise in full by the underwriters of their option to purchase 1,650,000 additional shares). Olema’s common stock is listed on the Nasdaq Global Select Market under the symbol “OLMA.”

Olema is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema is headquartered in San Francisco, California.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Ali DeGolia and Paula Gergen. The intellectual property and technology transactions team included partner David R. Bauer and associates S. Dream Montgomery and Daniel P. Kearney. The tax team included partner Po Sit and associate Tyler Scheiner. Counsel Marcie A. Goldstein provided FINRA advice. Associate J. Taylor Arabian provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post